|
US6887471B1
(en)
|
1991-06-27 |
2005-05-03 |
Bristol-Myers Squibb Company |
Method to inhibit T cell interactions with soluble B7
|
|
WO1997013514A1
(en)
*
|
1995-10-10 |
1997-04-17 |
Pfizer Inc. |
Nk-1 receptor antagonists for prevention of neurogenic inflammation in gene therapy
|
|
US20030219863A1
(en)
*
|
1997-01-31 |
2003-11-27 |
Bristol-Myers Squibb Company |
Soluble CTLA4 mutant molecules and uses thereof
|
|
US7094874B2
(en)
*
|
2000-05-26 |
2006-08-22 |
Bristol-Myers Squibb Co. |
Soluble CTLA4 mutant molecules
|
|
CZ303959B6
(cs)
*
|
2000-07-03 |
2013-07-17 |
Bristol-Myers Squibb Company |
Solubilní CTLA4 fúzní molekula, farmaceutický prostredek s jejím obsahem a její pouzití
|
|
US20040022787A1
(en)
|
2000-07-03 |
2004-02-05 |
Robert Cohen |
Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
|
|
HUP0303930A3
(en)
*
|
2001-01-26 |
2012-09-28 |
Univ Emory |
Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
|
|
PT1397153E
(pt)
|
2001-05-23 |
2008-06-12 |
Bristol Myers Squibb Co |
Métodos para proteger um transplante alogénico de ilhéus utilizando moléculas mutantes de ctla4 solúveis
|
|
US20030086903A1
(en)
*
|
2001-11-02 |
2003-05-08 |
Genvec, Inc. |
Therapeutic regimen for treating cancer
|
|
RU2375077C2
(ru)
*
|
2002-05-02 |
2009-12-10 |
Юниверсити Оф Коннектикут Хелт Сентер |
Использование белков теплового шока для повышения эффективности терапий антителами
|
|
DE602004025726D1
(de)
*
|
2003-11-14 |
2010-04-08 |
Genvec Inc |
Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
|
|
US7588772B2
(en)
*
|
2006-03-30 |
2009-09-15 |
Board Of Trustees Of The Leland Stamford Junior University |
AAV capsid library and AAV capsid proteins
|
|
HUE036180T2
(hu)
|
2006-09-26 |
2018-06-28 |
Infectious Disease Res Inst |
Szintetikus adjuvánst tartalmazó vakcina készítmény
|
|
US20090181078A1
(en)
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
|
EP2222697B1
(en)
*
|
2007-11-01 |
2012-12-05 |
Perseid Therapeutics LLC |
Immunosuppressive polypeptides and nucleic acids
|
|
RU2732574C2
(ru)
|
2009-06-05 |
2020-09-21 |
Инфекшес Дизиз Рисерч Инститьют |
Синтетические глюкопиранозиллипидные адъюванты
|
|
US9605844B2
(en)
*
|
2009-09-01 |
2017-03-28 |
Cree, Inc. |
Lighting device with heat dissipation elements
|
|
EP2621514B1
(en)
|
2010-09-28 |
2016-09-21 |
KAHR Medical (2005) Ltd |
Compositions and methods for treatment of hematological malignancies
|
|
WO2012141984A1
(en)
|
2011-04-08 |
2012-10-18 |
Immune Design Corp. |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
|
PT2811981T
(pt)
|
2012-02-07 |
2019-06-12 |
Infectious Disease Res Inst |
Formulações adjuvantes melhoradas que compreendem os agonistas de tlr4 e os seus métodos de utilização
|
|
CN107540730B
(zh)
|
2012-05-16 |
2021-07-16 |
免疫设计公司 |
用于hsv-2的疫苗
|
|
HK1214510A1
(zh)
|
2013-04-18 |
2016-07-29 |
Immune Design Corp. |
用於癌症治疗的gla单一疗法
|
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
|
AU2017268144B2
(en)
|
2016-05-16 |
2021-07-22 |
Access To Advanced Health Institute |
Formulation containing TLR agonist and methods of use
|
|
EP3463300A1
(en)
|
2016-06-01 |
2019-04-10 |
Infectious Disease Research Institute |
Nanoalum particles containing a sizing agent
|
|
US20200276299A1
(en)
|
2017-09-08 |
2020-09-03 |
Infectious Disease Research Institute |
Liposomal formulations comprising saponin and methods of use
|